Integrating Radiomics Signature into Clinical Pathway for Patients with Progressive Pulmonary Fibrosis
Interstitial lung diseases (ILDs) are a heterogeneous group of pulmonary disorders characterised by variable degrees of inflammation, interstitial thickening, and fibrosis leading to distortion of the pulmonary architecture and gas exchange impairment. There are approximately 200 different entities...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/15/3/278 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Interstitial lung diseases (ILDs) are a heterogeneous group of pulmonary disorders characterised by variable degrees of inflammation, interstitial thickening, and fibrosis leading to distortion of the pulmonary architecture and gas exchange impairment. There are approximately 200 different entities in this category. ILDs are commonly classified based on several criteria, including causes, clinical features, and radiological patterns. Chest HRCT is the gold standard for the recognition of lung alteration patterns underlying interstitial lung diseases (ILDs), diagnosing specific patterns, and evaluating radiologic progression. Methods based on artificial intelligence (AI) may be used in computational medicine, especially in image-based specialties such as radiology. The evolving field of radiomics offers a unique and non-invasive approach to extracting quantitative information from medical images, particularly high-resolution computed tomography (HRCT) scans. This comprehensive review explores the burgeoning role of radiomics in unravelling the intricacies of interstitial lung disease. It focuses on its potential applications in diagnosis, prognostication, and treatment response evaluation. |
|---|---|
| ISSN: | 2075-4418 |